---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-110552"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2024-10-22T23:59:59+00:00"
generated_at: "2026-05-30T11:38:28.801328+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TELA Bio reports preliminary Q3 revenue of $19M (+26% YoY); implements cost cuts

## Summary
- Revenue $19.0M for Q3 2024 vs $15.1M in Q3 2023, a 26% increase.
- Gross margin ~68% vs 69% in prior-year quarter.
- Cash and equivalents $17.3M at Sept 30, 2024, down from $46.7M at Dec 31, 2023.
- Cost-cutting measures expected to reduce FY2025 operating expenses by $5M-$10M annualized.

## SEC filing metadata
- accession: 0001104659-24-110552
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2024-10-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465924110552/0001104659-24-110552-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465924110552/tm2426600d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-110552
- JSON: https://secwatch.observer/filing/0001104659-24-110552.json
- Plain text: https://secwatch.observer/filing/0001104659-24-110552.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.